Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 7, 2025Journal of Biochemical and Molecular Toxicology

Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJing YangQQQing QiaoNLNa Lin

Discussion

Loading...

Member takes

Overview

Review reveals PROTACs effectively target cancer proteins like KRAS and EGFR, suggesting new therapeutic strategies.

Key Points

  • PROTACs offer a novel method to degrade cancer-initiating proteins, presenting a potential breakthrough in cancer treatment.
  • Preclinical studies show PROTACs can efficiently target mutations in KRAS, EGFR, and ALK, showing promise against resistant cancer forms.
  • This research focuses on the role of the ubiquitin-proteasome system in advancing therapeutic agents via PROTAC technology.
  • Developing safer cancer treatments through PROTACs highlights their significance in overcoming conventional therapy limitations.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d19b9https://doi.org/10.1002/jbt.70427
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment2025 · 18 citations
  2. 2PROTACs as a New Tactic to Treat Cancer2025
  3. 3Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review2026 · 1 citations
  4. 4Targeted Protein Degradation Technology: A Novel Strategy for Cancer Therapy2024
  5. 5Anticancer Therapy with Proteolysis-targeting Chimeras [PROTACs] Targeting Towards the Tumor-microenvironment: Development, Current State and Prospects2024 · 1 citations